Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in RA-ILD (RAILDTo)
NCT05246293Phase 2Unknown
- Sponsor
- Instituto Nacional de Enfermedades Respiratorias
- Start
- Aug 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tofacitinib in rheumatoid arthritis (RA) and interstitial lung disease (ILD), sponsored by Instituto Nacional de Enfermedades Respiratorias. Primary endpoint: Adverse Events at 52 weeks. Status: unknown.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT05246293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05246293.